TransCode Therapeutics Inc. RNAZ
1.69
0.04
2.42%
as of 25 Sep
- Market cap
- $27.9M
- P/E
- 0.0×
Follow RNAZ
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(1,764.97%) | (872.24%) | (757.04%) | 429.61% | |
| (592.93%) | (42.75%) | (51.30%) | (58.12%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(1,506.55%) | (192.31%) | (372.93%) | (831.37%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(17.42) | (28.33) | (23.33) | (23.62) | |
Free Cash Flow |
(14.52) | (19.54) | (21.40) | (22.61) | |
Capital Expenditures |
— | (0.02) | — | — | |
| Other line items | |||||
Cash ROIC |
(340.71%) | (69.33%) | (151.90%) | 117.06% | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.01 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | — | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.53 | 0.54 | 0.49 | 0.49 | |
Depreciation/Fixed assets |
9.66 | 0.31 | 0.25 | 0.30 | |
Capex/Depreciation |
0.00 | (0.22) | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(17.42) | (28.30) | (23.33) | (23.62) | |
Capex per Share |
0.00 | (0.04) | 0.00 | 0.00 | |
Capex to Sales |
— | 0.00 | — | — | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates